[ Inside the business ]

CRL stock analysis

CRL · Charles River Laboratories International, Inc.

Services-commercial physical and biological research. Shrinking 2%.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 1.5× sales in 5 yrs. Evidence: sales −2% · 4¢ profit/$1.

01 What's priced in?1.5× sales in 5 yrs
Sales now$4.0B
Needed in 5 yrs$6.1B
Backlog$675M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales −2%, steady
No customer over 10%
Backlog $675M · 0.2× salesPrepaid $204MSales −2%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 4¢ per $1, falling
'21'22'23'24'254¢
Before running costs: 84% → 84%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −1.9%/yrDebt $2M
07 What could break it?2 to watch
  • Insiders sold $52M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +1%, −3%, then −2% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.3× the market. In the 2008 crisis it fell 57% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

60% Discovery and Safety Assessment Segment.

Discovery and Safety Assessment Segment 60% · Research Models and Services Segment 21% · Manufacturing Support Segment 19%

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.6× the economy.

The government expects its industry, scientific research and development services, to grow 3.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

5 of 10 years.

Returns beat its 9.6% cost of capital in 5 of the last 10 years. Gross margin went from 84% to 84%.

Future bets

6% on equipment.

$223M a year on equipment and buildings.

All figures from Charles River Laboratories International, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.